Avalyn Pharma Inc. (AVLN)

What diseases does Avalyn target?

Avalyn Pharma focuses on rare interstitial lung diseases, chiefly idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). These are life-limiting conditions characterized by progressive scarring of lung tissue. The company’s approach is to reformulate established small-molecule therapies into inhaled versions, aiming to deliver treatment directly to the lungs while potentially reducing systemic side effects.

Why inhaled instead of oral?

Orally delivered anti-fibrosis agents already exist on the market. Avalyn’s rationale is that inhaling the medication concentrates it at the site of disease, potentially improving efficacy and tolerability. Inhaled delivery also allows for lower systemic exposure, which historically has been a limiting factor in patients taking oral forms of these drugs over long periods.

Who funds and backs this company?

The biotech is backed by Novo Nordisk, the Copenhagen-based global pharma giant, which invested early on. The company went public on the Nasdaq in April 2026, raising $300 million in an oversized IPO—a testament to investor appetite for late-stage respiratory drug development despite a crowded pulmonary fibrosis space.

What is in the pipeline?

The lead program, AP01, is an inhaled formulation of pirfenidone in Phase 2 trials. AP02, an inhaled version of nintedanib, is also in clinical development. AP03, a preclinical-stage fixed-dose combination of both drugs inhaled together, rounds out the early portfolio. All three are intended to treat fibrotic lung disease.

Is Avalyn a monoclonal-antibody company?

No. Avalyn is a small-molecule play centered on reformulation and delivery innovation. Pirfenidone and nintedanib are existing drugs with established modes of action; the company’s wager is that improving how they reach the lung will unlock clinical and commercial advantages where oral dosing has hit a ceiling.